A novel role for the integrin-binding III-10 module in fibronectin matrix assembly by unknown
A Novel Role for the Integrin-binding III-10 
Module in Fibronectin Matrix Assembly 
Denise C. Hocking, Renotta K. Smith, and Paula J. McKeown-Longo 
Department of Physiology and Cell Biology, Neil Hellman Medical Research Building, Albany Medical College, Albany, 
New York 12208 
Abstract. Fibronectin matrix assembly is a cell-depen- 
dent process which is upregulated in tissues at various 
times during development and wound repair to support 
the functions of cell adhesion, migration, and differenti- 
ation. Previous studies have demonstrated that the ot5131 
integrin and fibronectin's amino terminus and III-1 
module are important in fibronectin polymerization. 
We have recently shown that fibronectin's III-1 module 
contains a conformationally  sensitive binding site for fi- 
bronectin's amino terminus (Hocking, D.C., J. Sottile, 
and P.J. McKeown-Longo. 1994. J. Biol. Chem. 269: 
19183-19191).  The present study was undertaken to de- 
fine the relationship between the ot5131 integrin and fi- 
bronectin polymerization. Solid phase binding assays 
using recombinant III-10 and II1-1 modules of human 
plasma fibronectin indicated that the III-10 module 
contains a conformation-dependent  binding site for the 
III-1 module of fibronectin. Unfolded III-10 could sup- 
port the formation of a ternary complex containing 
both III-1 and the amino-terminal 70-kD fragment, sug- 
gesting that the III-1 module can support the simulta- 
neous binding of III-10 and 70 kD. Both unfolded III- 
10 and unfolded III-1 could support fibronectin bind- 
ing, but only III-10 could promote the formation of di- 
sulfide-bonded multimers of fibronectin in the absence 
of cells. III-10-dependent multimer formation was in- 
hibited by both the anti-III-1 monoclonal antibody, 
9D2, and amino-terminal fragments of fibronectin. A 
fragment of III-10, termed III-10/A, was able to block 
matrix assembly in fibroblast monolayers. Similar re- 
suits were obtained using the III-10A/RGE fragment, 
in which the RGD site had been mutated to RGE, indi- 
cating that III-10/A was blocking matrix assembly by a 
mechanism distinct from disruption of integrin binding. 
Texas red-conjugated recombinant 111-1,2 localized to 
[31-containing sites of focal adhesions on cells plated on 
fibronectin or the III-9,10 modules of fibronectin. 
Monoclonal antibodies against the III-1 or the 11I-9,10 
modules of fibronectin blocked binding of III-1,2 to 
cells without disrupting focal adhesions. These data 
suggest that a role of the tXs~  1 integrin in matrix assem- 
bly is to regulate a series of sequential self-interactions 
which result in the polymerization of fibronectin. 
F 
IBRONECTINS are a family of high molecular weight, 
multidomain glycoproteins composed of two struc- 
turally similar subunits which are joined at the car- 
boxyl terminus by disulfide  bonds (17). Fibronectin, like 
many other proteins of the extraceUular matrix, is a mosaic 
protein  composed  of modular units  (17). The  primary 
structure of fibronectin is organized into three types of 
repeating homologous units,  termed types I, II, and III 
(17, 30). These modules in turn are organized into func- 
tional domains which have been shown to contain multiple 
binding sites, including those for sulfated glycosaminogly- 
cans, gelatin, fibrin, and cell surface integrin receptors (26, 
30, 51). 
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Fibronectin is secreted as a dimer into the blood and 
other body fluids, where it circulates  at micromolar con- 
centrations as a soluble, protomeric molecule. In addition, 
an  insoluble,  multimeric  form  of  fibronectin  is  found 
within the extracellular spaces of connective tissue, base- 
ment membranes, and cultured cells (17). This multimeric 
form of fibronectin is its primary functional form, mediat- 
ing a variety of adhesive and migratory events during em- 
bryogenesis,  angiogenesis, thrombosis and hemostasis,  in- 
flammation, and wound repair (17). 
Polymerization of soluble fibronectin into insoluble fibrils 
is a dynamic, multistep,  cell-dependent process which oc- 
curs  at the surface of substrate-attached cells  (28). The 
mechanism by which  a  fibronectin matrix is  assembled, 
however, is only partially understood. In one of the initial 
steps of matrix assembly, cell surfaces bind the amino-ter- 
minal region of fibronectin in a reversible  and saturable 
manner (22, 35). Subsequent homophilic-binding  interac- 
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bilized  high  molecular mass  multimers  (5,  24,  25).  The 
molecule(s)  which  mediates  the  initial  binding  of  the 
amino terminus of fibronectin to cell surfaces has not been 
identified.  These  amino-terminal  binding  sites,  termed 
matrix assembly sites (22), have been defined operation- 
ally by ligand binding assays using t25I-labeled amino-ter- 
minal fragments of fibronectin (22, 35). The expression of 
these binding sites on cell surfaces has been shown to be 
regulated by the a5131 integrin receptor for fibronectin (9). 
Cellular adhesion  to fibronectin is  mediated primarily 
by the  ~5131 integrin,  which  binds  to fibronectin via  the 
Arg-Gly-Asp sequence contained within the III-10 mod- 
ule (16, 32). The importance of the c~5131 integrin receptor 
for fibronectin in the assembly of a fibronectin matrix has 
been demonstrated in several studies. Overexpression of 
the a5131 integrin in Chinese hamster ovary (CHO) cells re- 
sults in an increase in the level of fibronectin deposition by 
these cells (11). Transfection of the t~  5 subunit into mutant 
CHO cells deficient in ct  5 expression restores the ability of 
these ceils to assemble a fibronectin matrix (48). Antibod- 
ies directed against either a5131 (2) or the integrin-binding 
site  in  the  111-10 module  of fibronectin  (20)  inhibit  fi- 
bronectin fibril formation. In addition, anti-131 integrin an- 
tibodies have been shown to inhibit binding of the amino- 
terminal  70-kD  fragment  to  the  cell surface, suggesting 
that the oL5131  integrin can regulate the expression of matrix 
assembly sites (9). 
We recently identified  a  conformation-dependent site 
within the III-1 module of fibronectin which binds to the 
amino-terminal  region  of fibronectin  with  high  affinity 
(15).  Based  on these  and  other studies,  we  proposed  a 
model in which the fibronectin molecule, bound to the in- 
tegrin, undergoes conformational changes resulting in the 
exposure of the 70-kD binding site in III-1. These series of 
interactions  form a  "nucleation  site"  which  serves  as  a 
template for the subsequent binding and incorporation of 
incoming fibronectin molecules into the extracellular ma- 
trix. The present study was undertaken to identify a mech- 
anism by which the cryptic 70-kD binding site in III-1 may 
be exposed in the intact fibronectin molecule. We postu- 
lated  that  regulation  of the  conformation of the  70-kD 
binding site in III-1 by the a5131 integrin may be mediated 
by an  interaction between fibronectin's integrin-binding 
III-10 module and the 70-kD-binding 111-1 module. In this 
study, we have used recombinant fibronectin modules to 
characterize a conformation-dependent binding site in the 
III-10 module of fibronectin which binds to III-1. The in- 
teraction of III-1 in intact fibronectin with III-10 promotes 
the formation of disulfide-stabilized high molecular mass 
multimers in the absence of cells, via an interaction involv- 
ing the amino-terminal region of fibronectin. A  fragment 
of III-10 which blocks the formation of in vitro fibronectin 
multimers also inhibits fibronectin polymerization by cells. 
In addition, we examined the expression of III-1 binding 
sites on cell surfaces and found that exogenously added 
111-1,2 localizes at regions of focal adhesions and that lo- 
calization to focal adhesions  is  dependent on the  III-10 
module. Taken together, these data suggest that Ot51~  1 inte- 
grin regulation of fibronectin matrix assembly may be me- 
diated, in part, by an interaction between the III-1 and III-10 
modules of fibronectin. 
Materials and Methods 
Reagents 
Materials for autoradiography were from Kodak (Rochester, NY). Gel 
electrophoresis supplies were from BioRad Labs (Richmond, VA). Un- 
less otherwise indicated, chemical reagents were obtained from Sigma 
Chem. Co. (St. Louis, MO). 
Cell Culture 
Human foreskin fibroblasts, A1-F, were a gift from Dr. Lynn Allen-Hoff- 
mann (University of Wisconsin, Madison, WI). A1-Fs were cultured in 
Dulbecco's modified Eagle's medium (DMEM) (GIBCO-BRL, Gaithers- 
burg, MD) supplemented with 10% FBS (Sterile Systems, Logan, UT). 
9D2 hybridoma cells (5) were a gift from Dr. Deane Mosher (University 
of Wisconsin, Madison, WI). Hybridoma cells were cultured in DMEM 
containing 20% heat-inactivated FBS. 
Gel Electrophoresis 
SDS-PAGE was performed according to Laemmli (19) using a discontinu- 
ous buffer system (BioRad Labs). Samples were diluted 1:1 in gel buffer 
containing 4% SDS and 20% glycerin in 0.05 M Tris, pH 6.8. Some sam- 
ples were reduced with 2%  13-mercaptoethanol before electrophoresis. 
Proteins were visualized with 0.1% Coomassie blue (47).  Iodinated pro- 
teins were visualized by autoradiography. III-10 preparations were char- 
acterized on 16.5%  polyacrylamide gels containing 13% glycerol, using a 
discontinuous tricine-SDS-PAGE system, according to  the  method  of 
Sh~igger and von Jagow (39). Proteins were visualized with 0.025% Serva 
blue G (Serva, Paramus, N J). 
Purification of  Fibronectin and Fibronectin Fragments 
Human plasma fibronectin was purified from a fibronectin- and fibrino- 
gen-rich by-product of Factor VIII production by ion exhange chromatog- 
raphy on DEAE-cellulose (Pharmacia LKB Biotechnology, Piscataway, 
NJ), as previously described (22). Fig. 1 shows a schematic of the various 
fragments used in this study. The 70-kD amino-terminal fragment of fi- 
bronectin was generated by limited digestion of intact fibronectin with 
cathepsin D, followed by gelatin affinity chromatography, as previously 
described (22).  The 70-kD  fragment was further cleaved into a  27-kD 
amino-terminal fragment and a 40-kD gelatin-binding fragment by limited 
digestion with trypsin (4). The 27- and 40-kD fragments were then sepa- 
rated by gelatin affinity chromatography. A  preparation containing the 
160/180-kD  cell- and gelatin-binding fragments was generated by limited 
digestion of fibronectin with trypsin, and then isolated by retention on gel- 
atin-Sepharose, as previously described (22).  Purity of all fragments was 
assessed by SDS-PAGE and proteins were frozen at -80°C until use. 
Preparation of  Recombinant Fibronectin Modules 
Recombinant III-1 and III-2 were expressed in BL21(DE3) bacteria as fu- 
sion proteins composed of glutathione-S-transferase (GST) 1 and either 
III-1 or III-2, as previously described (15). To separate III-1 or III-2 from 
GST, fusion proteins were incubated with TPCK-trypsin-agarose beads 
(1 U/mg) for 30 min at 20°C. After incubation, the TPCK-trypsin-agarose 
beads were removed by centrifugation. III-1 was further purified by pass- 
ing  the  digested  material  over  a  fast  protein  liquid  chromatography 
(FPLC) SP-5PW column (Waters, Boston, MA), as previously described 
(15). The III-2 digest was purified by passing the digest over an FPLC Pro- 
tein-Pak Q  8HR column (Waters). III-2 was eluted with a salt gradient 
from 0.015 M NaCI, 20 mM phosphate, pH 7.0 to 0.25 M NaCl, 20 mM 
phosphate, pH 7.0. III-2 eluted from the column in one sharp peak and 
was the only protein detected by SDS-PAGE. 
Polymerase chain reaction (PCR) was used to amplify human fibronec- 
tin cDNA encoding the first and second type III modules (III-1,2) of fi- 
bronectin (bases 1745 through 2347).  This DNA  encodes amino acids 
from Ser-578 through Thr-778.  Bases are numbered from the A  in the 
codon for the first amino acid of the mature protein (EMBL accession 
number X02761),  and amino acids are numbered from the amino-terminal 
1. Abbreviations used in this paper. FPLC, fast protein liquid chromatog- 
raphy; GST, glutathione-S-transferase. 
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Figure 1.  Fibronectin fragments. Schematic representation of fi- 
bronectin molecule. Shown are the 27- (cathepsin-trypsin: amino- 
terminal), 40- (cathepsin-trypsin: gelatin-binding), 70- (cathepsin: 
amino-terminal), and  160/180-kD  (trypsin; gelatin and cell bind- 
ing)  fragments.  Type  I  modules,  rectangles;  type  II  modules, 
ovals; type 1II modules, squares. 
pyroglutamic acid (30). PCR was also used to amplify human fibronectin 
cDNA  encoding the fifth type  III  module (111-5) (bases 2906 through 
3175; Lys 965 through Leu 1054), the tenth type III module (III-10) (bases 
4259 through 4518;  Val-1415 through Thr-1508), and the ninth and tenth 
type III modules (Ill-9,10) of fibronectin (bases 3989 through 4518;  Gly- 
1325  through  Thr-1508).  The  sense  primers  for  the  111-1,2 construct 
(5'-CCCGGATCCAGTGGTCCTGTCGAAGTATT), the 111-5 construct 
(5'-CCCGGATCCAAACTGGATGCTCCCACTAACC), and the 1II-10 
construct (5'-CCCGGATCCGTITCTGATGTTCCGAGGGAC) were syn- 
thesized with a BamHI site (shown in bold) at the 5' end. The sense primer 
for  the II1-9,10  construct (5'-CCCAGATCTGGTCTTGATTCCCCAAC- 
TGG) was synthesized with a BgllI site (shown in bold) at the 5' end. The 
antisense primers for the III-1,2 construct (5'-CCCGAATI'CCTATGT- 
TG'ITTGTGAAGTAGACAGG), the 1II-5 construct (5'-CCCGAATrC- 
CTACAGTGTGGTAAAGACTCCAGTG),  and  the  I11-10  construct 
(5'-CCCGAATI'CCTATGTTCGGTAATTAATGGAAATTG)  were syn- 
thesized with an EcoRI site (shown in bold) at the 5' end. The antisense 
primer  for  the  Ill-9,10  construct  (5'-CCCCCCGGGCTATGTTCGG- 
TAATTAATGGAAATTG) was synthesized with a SmaI site (shown in 
bold) at the 5' end. Underlined bases introduce a stop codon after the last 
base in the sequence to be amplified. The III-10/RGE mutant was produced 
using recombinant  PCR  (14).  The  two  mutant  primers  were  5'-CCG- 
TGGAGAAAGCCCCGCAAGC (sense primer) and 5'-GC'ITGCGGG- 
GCTITCTCCACGG (antisense primer). The mutated base is shown in 
bold. The two outer primers used were the same as those used to amplify 
nonmutant 111-10. PCR was performed according to  established proce- 
dures (37), using human full-length fibronectin cDNA, pFH100 (a gift of 
Dr. Jean Thiery, Paris, France) as a template. After restriction enzyme di- 
gestion, the PCR amplified DNA was cloned into the bacterial expression 
vector pGEX-2T (Pharmacia).  PCR  amplified DNA was sequenced to 
confirm that no base changes had been introduced during amplification of 
the DNA and to establish the presence of the mutated base in III-10/RGE 
(38),  DNA encoding either 111-1,2, III-10,  III-10/RGE,  or  111-9,10 was 
cloned in frame with the bacterial glutathione-S-transferase DNA. 
DNA was transfected into BL21(DE3) bacteria using standard proce- 
dures (37). Fusion proteins were isolated by passing bacterial lysates over 
glutathione agarose, as previously described (15).  Fusion proteins were 
then digested with l  U/mg Tt'CK-trypsin-agarose for 30 min at 20°C. This 
cleavage gives rise to an additional glycine and serine residue at the amino 
terminus of the isolated modules. The Ill-5 and 111-1,2 constructs were 
isolated  by passing the digested materal over an FPLC Protein-Pak  Q 
8HR column (Waters) and eluting with a salt gradient from 0.015 M NaCI, 
20 mM phosphate, pH 7.0 to 0.25 M  NaCI, 20 mM phosphate, pH 7.0. 
Amino acid sequencing of III-1,2 yielded the following amino terminal se- 
quence:  GSSGPVEVFI,  corresponding to  the region  beginning at  the 
amino-terminus of 1II-1, starting at Ser  578. 111-9,10 was isolated by passing 
the digested material over a glutathione agarose column. To isolate II1-10, 
the TPCK-trypsin--digested material was passed twice over a high perfor- 
mance liquid chromatography Protein-Pak 125 gel filtration column (Wa- 
ters). For some studies, GST/III-10 and GST/III-10/RGE  were digested 
with 0.5 U/mg trypsin-acrylic beads  (non-TPCK-treated)  for 30 min at 
20°C (III-10A and III-10A/RGE) and purified as described for III-10. The 
apparent molecular masses of the 111-10 preparations were determined by 
tricine-SDS-PAGE and are as follows: III-10  =  17 kD, III-10A and III- 
10A/RGE =  14.5 kD. Amino acid sequencing of III-10, III-10A, and III- 
10A/RGE yielded identical amino-terminal sequences: GSVSDVPRDL. 
This sequence corresponds to the region beginning at the amino terminus 
of III-10, starting at Val-1415. 
Preparation of 9D2 lgG and Fab' Fragments 
Ascite~ of 9D2 were prepared as described (13). Immunoglobulins (IgGs) 
were isolated by passing the ascites over a protein A-Sepharose CL-4B 
column (Pharmacia)  equilibrated with  100  mM sodium phosphate (pH 
7.0). Bound IgG was eluted with 1 M acetic acid, 100 mM glycine (pH 3.0). 
The eluate was neutralized to pH 7.4 with 1 M Tris (pH 10.0) and dialyzed 
against PBS. 9D2 IgG, diluted in 0.1 M  sodium citrate buffer, pH 4, was 
digested with pepsin (1:200 wt/wt)  for 15 h  at 37°C to produce F(ab')2 
fragments (13). Monovalent Fab' fragments were obtained after reduction 
of F(ab')2 with 10 mM 13-mercaptoethanol for 2 h at 37°C and alkylation 
with 10 mM iodoacetamide for 4 h at 20°C (13). Fab' fragments were dia- 
lyzed against PBS, and then passed over a  protein A-Sepharose CL-4B 
column (Pharmacia) to remove intact IgG. Purity was assessed by SDS- 
PAGE and aliquots were stored at -80°C before use. Nonimmune mouse 
F(ab')2 fragments (Cappel, Durham, NC) were similarly reduced, alky- 
lated, and dialyzed against PBS to produce Fab' fragments. 
Iodination of  Fibronectin and Fibronectin  Fragments 
For solid phase and cell binding assays, 27 and 70 kD, fibronectin, and III-1 
and III-2 were iodinated with 1.0 mCi NalZSI (New England Nuclear, Bos- 
ton, MA) using chloramine T, as previously described (22). The iodination 
reaction was stopped  with sodium metabisulfite (Fisher Scientific, Fair 
Lawn, N J)  and free iodine was removed by chromatography on G-25M 
Sephadex (Pharmacia). Iodinated proteins were dialyzed against PBS and 
frozen at -80°C until use. Integrity of the labeled proteins was assessed by 
gel electrophoresis and autoradiography. Specific activities of labeled pro- 
teins ranged from 2.1-11.9 ×  104 Ci/mol. 
Solid Phase Binding  Assay 
Solid phase binding assays were performed essentially as described (15). 
III-1, III-2, III-5, or III-10 was diluted to 10 ixg/ml in PBS containing 2 mM 
PMSF, incubated for 10 min at 90°C, and added to wells of 24-well cluster 
plates (Falcon, Bedford, MA). Plates were then incubated for 90 rain at 
80°C. For studies involving nondenatured proteins, proteins were diluted 
to 10 p,g/ml in PBS containing 2 mM PMSF, added to wells, and plates 
were incubated at 20°C for 90 min. After this incubation, unbound protein 
was removed and unreacted sites were  blocked with  1%  protease-free 
BSA (Intergen Co., Purchase, NY) in PBS. In studies (not shown) using 
radiolabeled proteins, ~50% less protein bound to wells coated at 80°C 
than at 20°C. For some studies, wells were coated with 10 mg/ml BSA in 
PBS for 2 h at 37°C. Protein-coated wells were washed three times with PBS 
containing 0.2% BSA and incubated at 37°C with 106 cpm/ml 125I-labeled 
protein diluted in PBS with 0.2%  BSA. Nonspecific binding was deter- 
mined in separate wells by the addition of excess unlabeled protein to the 
binding medium. Specific binding was calculated by subtracting nonspe- 
cific binding from total binding. 
Cell Binding  Assays 
1251-fibronectin  binding assays were  conducted  as previously described 
(21). Briefly, A1-F fibroblasts were seeded at 5 ×  104 cells/well into 24-well 
cluster dishes (Falcon) in DMEM containing 10%  FBS  and allowed to 
grow to confluence for 3-4 d. Cells were washed three times with serum- 
free DMEM and incubated for 24 h with 0.5 x  106 cpm/ml 125I-fibronectin 
in DMEM containing 0.2% BSA in the absence or presence of either III- 
10, III-10A, or III-10A/RGE. After this incubation, unbound protein was 
removed, cells were washed with PBS, and bound protein was solubilized 
with 1 N  NaOH. Nonspeciflc binding was determined by incubating the 
cells in the presence of excess unlabeled fibronectin (400 p~g/ml). 
Immunofluorescence Microscopy 
III-1,2 was diluted to 0.5 mg/ml in 0.05 M sodium borate buffer, pH 9.0, 
and directly conjugated to Texas red sulfonyl chloride (Molecular Probes, 
Eugene, OR) using N,N-dimethyl formamide, according to the manufac- 
turer's protocol. The protein conjugate was separated from unreacted Texas 
red by gel filtration chromatography on G-25M Sephadex (Pharmacia). 
Protein concentration was determined from the absorbance at 280 nM. 
18-mm glass coverslips were coated for 2 h at 37°C with 10 Ixg/ml of ei- 
ther fibronectin, the 160/180-kD fragment of fibronectin, the 111-9,10 mod- 
ules of fibronectin, vitronectin, or laminin in PBS. Unbound protein was 
removed and A1-F fibroblasts were seeded onto coverslips in 12-well clus- 
ter dishes (Falcon) at 4  x  104 cells/well in DMEM containing 0.2% BSA. 
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at a concentration of 20 ixg/ml (23). Cells were then incubated overnight 
at  37°C.  After this incubation, 10  p,g/ml Texas red-labeled-llI-1,2  was 
added directly to the culture media and cells were incubated an additional 
90 rain. In some studies, before the incubation with Texas red III-1,2, 50 
p,g/ml of either 9D2, the monoclonal antibody clone 3E3 (31) (GIBCO 
BRL), or the monoclonal antibody LAB (a gift of Deane Mosher, Univer- 
sity of Wisconsin, Madison, WI) were added directly to the culture me- 
dium. After a 1-h incubation, Texas red 11I-1,2 was added to the culture 
media and ceils were incubated an additional 90 min. The epitope recog- 
nized by the Lab monoclonal antibody is contained within the region 111-4 
to 111-8 (5). The epitope recognized by the 3E3 monoclonal antibody is 
contained within the 15-kD cell-binding fragment of ftbronectin (31). Me- 
dia was then removed and cells were fixed with 3.7% paraformaldehyde in 
Small's  cytoskeletal  buffer  (41)  and  permeabilized  with  0.5%  Triton 
X-100. Cells were stained for 1~] integrins using the monoclonal anti-13  t an- 
tibody, AIIB2 (a gift of Caroline Damsky, University of California, San 
Francisco,  CA),  followed  by  incubation  with  a  fluorescein-conjugated 
goat anti-rat antibody (Cappel) for 60 min. Cells were washed, mounted, 
and then examined using an Olympus microscope. 
Results 
Identification  of a Binding Site within the 
Integrin-binding  III-10 Module of Fibronectin 
for llI-1 
Cellular adhesion to fibronectin is mediated primarily by 
the a5[~1 integrin, which binds to fibronectin via the Arg- 
Gly-Asp sequence contained within the III-10 module (16, 
32, 34). A role for the integrin in fibronectin matrix assem- 
bly has previously been demonstrated in studies in which 
addition  of antibodies  directed  against the  e~5[~  1 integrin 
was shown to inhibit fibronectin polymerization and de- 
crease 70  kD  binding  to cell surfaces  (9).  Our  previous 
study indicated  that the III-1 module of fibronectin con- 
tains  a  conformation-dependent  site  which  binds  to the 
amino-terminal region of fibronectin with high affinity (15). 
Based on these studies, we postulated that expression of 
70 kD binding sites within the III-1 module may be regulated 
by an interaction between the III-1 and III-10 modules. To 
determine whether III-1 binds to III-10, solid phase bind- 
ing studies  were conducted  using recombinant III-1 and 
III-10 modules. As shown in Fig. 2 A, 125I-III-1 bound to 
wells coated with heat-denatured III-10, whereas 125I-III-2 
did not. In addition, l:SI-III-1 did not bind to III-10 which 
was not heat-denatured before its adsorption onto tissue 
culture plastic (Fig. 2 A), suggesting that the binding site in 
the III-10 module for III-1 is conformation dependent. To 
determine whether III-1 bound  selectively to heat-dena- 
tured III-10, the binding of t25I-III-1 to other heat-dena- 
tured modules was assessed. As shown in Fig. 2 B, both 
heat-denatured III-10 and heat-denatured III-5 supported 
higher levels of 125I-III-1 binding than did heat-denatured 
III-1 or heat-denatured  III-2. These results indicate  that 
III-1 can bind to heat-denatured III-10 and may also bind 
to other heat-denatured  type III modules in solid phase 
binding  assays.  However,  in  additional  experiments  de- 
scribed in this study, we were unable to detect any func- 
tional significance for the interaction between III-1 and III-5. 
Inhibition of Fibronectin Binding to Heat-denatured 
III-10 by III-1 
To determine whether heat-denatured III-10 is able to rec- 
ognize  III-1 within  the  context  of the  intact  fibronectin 
molecule,  binding  of  radiolabeled  fibronectin  to  heat- 
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Figure 2.  1~I-III-1 binding to heat-denatured III-10. (A) 24-well 
plates were coated with 10 ixg/ml nonheat-denatured III-10 (III- 
10) or heat-denatured III-10 (HDIII-10), as indicated  under Ma- 
terials and Methods, and incubated for 60 min at 37°C with 0.5 × 
106 cpm/ml of either 1:5I-III-1 (closed bars) or 1251-111-2 (hatched 
bar). In B, 24-well plates were coated with either 10 ixg/ml of the 
following heat-denatured proteins: III-1 (HDIII-1),  11I-2 (HDIII-2), 
111-5 (HDIII-5),  or III-10 (HDIII-10), and incubated for 60 min at 
37°C with 0.5 ×  10 6 cpm/ml of 125I-III-1.  Plates were then rinsed, 
bound protein was solubilized  in  1 N NaOH, and radioactivity 
was determined. Nonspecific binding was determined in separate 
wells by performing the assay in the presence of 25 ixg/ml unla- 
beled 111-1 or 111-2. Nonspecific binding, which was ~30% of total 
binding, was subtracted from total binding to determine specific 
binding. Data are presented as the amount of protein bound per well 
and represent one of three experiments performed in duplicate. 
denatured III-10 was assessed in the presence of increasing 
concentrations of unlabeled III-1. Binding of 125I-labeled fi- 
bronectin to heat-denatured III-10 was inhibited in a dose- 
dependent manner by 111-1 (Fig. 3). In contrast, 111-2 had 
no effect on fibronectin binding to heat-denatured  111-10 
(Fig.  3).  In  addition,  125I-fibronectin  binding  to  heat- 
denatured III-10 was inhibited by the addition of the anti- 
III-1 monoclonal antibody 9D2  (data not shown). These 
data indicate that intact fibronectin can bind to conforma- 
tionally altered III-10 and that this binding is dependent 
on the III-1 module. 
Inhibition of lII-I Binding to Heat-denatured III-I0 
by 9D2 
Previous studies  (5, 24, 25) have demonstrated a role for 
III-1 in self-interactive events thought  to be involved in 
the polymerization of fibronectin on cell surfaces. In ma- 
trix assembly assays done  on fibroblast monolayers, the 
anti-III-1 monoclonal  antibody,  9D2,  blocked the  poly- 
merization  of fibronectin by fibroblasts at a  step subse- 
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Figure 3.  125I-fibronectin  binding to heat-denatured  III-10. Plates 
were coated with 10 ~g/ml heat-denatured  III-10, as indicated un- 
der Materials  and  Methods,  and  incubated  for 60 min at 37°C 
with 0.5 ×  106 cpm/ml of ]25I-fibronectin  in the absence or pres- 
ence of increasing concentrations of unlabeled III-1 (e) or 11I-2 
(©). Plates were then rinsed, bound protein was solubilized in 1 N 
NaOH, and radioactivity was determined. Data represent one of 
three experiments performed in duplicate. 
quent to the initial amino-terminal binding of fibronectin 
to the cells (5).  The complementary site for III-1 binding 
was not identified. To determine whether 9D2 recognizes 
the III-10 binding site within the III-1 module, binding of 
1251-111-1 to heat-denatured III-10 was assessed in the pres- 
ence of increasing concentrations of either 9D2 or nonim- 
mune mouse Fab' fragments. As shown in Fig. 4 A, 9D2 
Fab' fragments inhibited  1251-111-1 binding to heat-dena- 
tured III-10 in a  dose-dependent manner. A  50%  inhibi- 
tion of 1251-11I-1 binding to heat-denatured III-10 was ob- 
tained at a concentration of 1 #xg/ml 9D2 Fab' (Fig. 4 A). 
This  concentration  of 9D2  is  similar  to  that  previously 
shown to cause a 50% inhibition of 125I-fibronectin binding 
to  cell  surfaces  (5).  In  contrast,  nonimmune  Fab'  frag- 
ments had no effect on 1251-111-1 binding to heat-denatured 
III-10 (not shown). 
We previously reported that the III-1 module contains a 
conformation-dependent binding site for the amino-termi- 
nal 70-kD fibronectin fragment (15).  To test whether 9D2 
inhibits the interaction of 70 kD with heat-denatured III-1, 
binding of 1251-70 kD to heat-denatured III-1 was assessed 
in the presence of increasing concentrations of 9D2 Fab' 
fragments. In contrast to the results described above (Fig. 
4 A), 9D2 Fab' fragments had no effect on the binding of 
~251-70 kD to heat-denatured III-1 (Fig. 4 B). The inability 
of 9D2 to block ]251-70 kD binding to heat-denatured III-1 
was not due to an inability of 9D2 to recognize the confor- 
mationally altered form of III-1. In separate studies using 
an enzyme-linked immunoassay (8), 9D2 recognized III-1 
and heat-denatured III-1 equally well (not shown). 
Binding of  Amino-Terminal Fragments 
to Heat-denatured IIl-lO in the Presence 
of IlV  l,2 
Solid phase binding assays were conducted to determine if 
a  complex could be formed between heat-denatured III- 
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Figure 4.  Inhibition of III-1 binding to heat-denatured  III-10 by 
9D2. Plates were coated with 10 ~g/ml of either heat-denatured 
III-10 (A) or heat-denatured  III-1 (B), as indicated under Materi- 
als and Methods. Plates coated  with heat-denatured  III-10 (A) 
were incubated for 60 min at 37°C  with 0.5 × 106 cpm/ml of ]251-111-1 
(~50 ng/ml) in the presence of increasing concentrations of 9D2 
Fab' fragments. Plates coated with heat-denatured  III-1 (B) were 
incubated for 60 min at 37°C with 0.5 × 106 cpm/ml of ]251-70 kD 
(,~100 ng/ml), in  the  presence  of increasing concentrations  of 
9D2 Fab' fragments. Plates were then rinsed, bound protein was 
solubilized in 1 N NaOH, and radioactivity was determined. Data 
represent one of three experiments performed in duplicate. 
10,  III-1, and  the  amino terminus  of fibronectin.  Tissue 
culture wells coated with heat-denatured III-10 were incu- 
bated with 125I-labeled 70 kD amino-terminal fragment of 
fibronectin in the absence or presence of either III-1,111-2, 
or III- 1,2. Whereas 1251-70 kD itself did not bind to heat- 
denatured III-10 (Fig.  5 A), preincubation of heat-dena- 
tured III-10 with increasing concentrations of 111-1,2 re- 
sulted in a dose-dependent increase in 1251-70 kD binding 
(Fig. 5 A). Similar results were obtained using the 1251-27- 
kD fragment (data not shown). In contrast, addition of III- 
1,2 to plates coated with heat-denatured Ill-5 did not pro- 
mote 1251-70 kD binding (Fig.  5 A). Neither III-1 nor Ill-2 
alone could support the formation of this ternary complex 
on heat-denatured  III-10 (Fig.  5 A).  In  parallel  studies 
(not  shown),  the  binding of 1251-111-1 to  heat-denatured 
III-10 was greater than the binding of ]251-111-1,2 to heat- 
denatured  III-10, indicating that  the  inability of III-1 to 
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Figure 5.  1251-70 kD binding to heat-denatured III-10 in the pres- 
ence  of II1-1,2. (A)  Plates  were  coated with  10  p.g/ml heat- 
denatured  III-10 (solid bars) or heat-denatured  Ill-5 (hatched 
bars), as indicated  under  Materials  and Methods.  Wells  were 
then incubated with 106 cpm/ml 1251-70 kD for 2 h at 37°C in the 
absence or presence of increasing concentrations  of 111-1,2, III-1 
(50 p~g/ml),  or Ill-2 (50 i~g/ml). Plates were rinsed, bound protein 
was solubilized in 1 N NaOH, and radioactivity was determined. 
Nonspecific  binding  was  determined in separate wells by per- 
forming the assay in the presence of 50 p.g/ml unlabeled 70 kD. 
Nonspecific binding, which was ~40% of total binding, was sub- 
tracted from total binding  to determine  specific  binding.  The 
amount of 70 kD bound was normalized to the amount of heat- 
denatured protein adsorbed to the plate. In B, wells coated with 
heat-denatured III-10 were incubated with 50 p.g/ml 111-1,2 and 
2 x  106 cpm/ml of 1251-27 kD in the absence  or presence of in- 
creasing concentrations  of either 9D2 (solid bars) or nonimmune 
(hatched bars) Fab' fragments.  Data are presented as percent of 
specific binding measured in the absence of antibody and repre- 
sent one of three experiments performed in duplicate. 
promote 1251-70 kD binding was not the result of decreased 
binding to heat-denatured III-10. These data suggest that 
the presence of II1-2 in the III-1,2 construct may stabilize 
111-1 in the appropriate conformation to support the ternary 
complex formation. As shown in Fig. 5 B, 1251-27 kD binding 
to the III-1,2/II1-10  complex was dependent on the binding of 
111-1 to heat-denatured 111-10, since addition of 9D2 Fab' 
fragments resulted in an inhibition of 1251-27 kD binding. Sim- 
ilar results were obtained using the 1251-70 kD fragment (data 
not shown). Taken together, these results indicate that a ter- 
nary complex can be formed in which III-1 simultaneously 
binds to both 111-10 and the amino terminus of fibronectin. 
Formation of Fibronectin Multimers by 
Heat-denatured III-10 
Upon binding to cells, fibronectin accumulates as high mo- 
lecular mass aggregates which do not penetrate the stack- 
ing gel when analyzed by SDS-PAGE. These aggregates, 
which are thought to represent fibronectin in the extracel- 
lular matrix, can be dissociated to monomeric fibronectin 
with reducing agents (21). Morla et al. (25) have recently 
shown that in the absence of cells, a fibronectin construct 
containing two thirds of the III-1 module can induce the 
formation of fibronectin multimers. The authors speculate 
that the activity of their III-1 construct may be masked in 
the intact fibronectin molecule but may be exposed on the 
cell surface as a result of fibronectin binding to the a5131 in- 
tegrin. To determine if the interaction of conformationally 
altered III-10 with III-1 within the intact fibronectin mole- 
cule  could  promote the formation of disulfide-stabilized 
high  molecular  mass  fibronectin  multimers,  solid  phase 
binding  assays were  conducted  using  assay wells  coated 
with  either  heat-denatured  III-10, heat-denatured  III-1, 
nonheat-denatured III-10, or BSA. Incubation of IzsI-fibro- 
nectin in wells coated with either heat-denatured III-10 or 
heat-denatured III-1 resulted in specific fibronectin binding 
(Fig. 6 A). Samples containing equal cpm were then ana- 
lyzed by SDS-PAGE followed by autoradiography. Incu- 
bation of 125I-fibronectin with heat-denatured III-10 resulted 
in the formation of high molecular mass fibronectin aggre- 
gates which did not penetrate the stacking gel (Fig. 6 B, ar- 
row). To quantitate these aggregates, gel slices were removed 
and  counted  (Fig.  6  C).  In  the  presence  of  a  reducing 
agent,  no high molecular mass aggregates were detected 
(Fig. 6 C); only monomeric subunits were present (Fig. 6 
B). In addition, the III-10 module must be conformation- 
ally altered in order to induce fibronectin multimer forma- 
tion, since incubation of 125I-fibronectin with wells coated 
with III-10 which was not heat-denatured did not result in 
either specific fibronectin binding (Fig. 6 A) or multimer 
formation (Fig. 6  C). Whereas 125I-fibronectin bound av- 
idly to wells coated with heat-denatured III-1 (Fig. 6 A), 
when  analyzed by SDS-PAGE,  no high  molecular mass 
multimers were detected  (Fig. 6 B, arrow and Fig. 6  C). 
The  binding  of fibronectin  to  heat-denatured  III-1 was 
completely inhibited by the addition of excess amino-ter- 
minal  70-kD  fragment  (not  shown),  indicating  that  fi- 
bronectin binding to heat-denatured III-1 was dependent 
upon the amino-terminal region. Heat-denatured III-5, al- 
though capable of binding III-1 in solid phase assays (Fig. 
2),  was  not  active  in  promoting  disulfide-stabilized  fi- 
bronectin multimers (data not shown). 
Inhibition of lII- l O-induced Fibronectin Multimers 
with 9D2 or 27 kD 
To test whether the III-1 module in intact fibronectin in- 
teracts with conformationally altered III-10 during the for- 
mation of fibronectin multimers, 125I-fibronectin was incu- 
bated in wells precoated with heat-denatured III-10, in the 
presence of increasing concentrations  of 9D2 Fab'  frag- 
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ments. Addition of 9D2 Fab' fragments resulted in a dose- 
dependent decrease in fibronectin binding (Fig. 7 A) and a 
parallel  decrease in multimer formation (not shown). In 
contrast,  nonimmune  Fab'  fragments  had  no  effect  on 
125I-fibronectin binding to heat-denatured III-10 (Fig. 7 A). 
Addition of either the 27-kD or 70-kD amino-terminal 
fibronectin fragment to cells blocks the polymerization of 
fibronectin on cell surfaces (22, 35). To determine whether 
the formation of fibronectin multimers on conformation- 
ally altered III-10 also involves the amino-terminal region 
of fibronectin,  125I-fibronectin  was  incubated  with  wells 
precoated with  heat-denatured  III-10 in the  presence  of 
increasing concentrations of the  27-kD  fibronectin  frag- 
ment. Addition of 27 kD resulted in a dose-dependent de- 
crease in fibronectin binding (Fig. 7 B) and a parallel de- 
crease  in  multimer  formation  (not  shown).  In  contrast, 
addition of the 40-kD gelatin-binding fibronectin fragment 
to the reaction had no effect (Fig. 7 B). These data indi- 
cate that both III-1 and the amino terminus are involved in 
the  formation  of  III-10-induced  disulfide-stabilized  fi- 
bronectin multimers.  In addition, these data suggest that 
the  intramolecular interactions  involved in the polymer- 
ization of fibronectin on cell surfaces and in the formation 
of III-lO-induced fibronectin multimers are similar. 
Figure 6.  125I-fibronectin  multimer formation on heat-denatured 
111-10. (A) 24-well plates were coated with either heat-denatured 
III-10 (HDIII-IO), heat-denatured III-1 (HDIII-1), nonheat-dena- 
tured  III-10 (1II-10), or BSA, as indicated under  Materials and 
Methods. Assay wells were incubated with 106 cpm/ml lzsI-fibro- 
nectin  in PBS/0.2%BSA for 18 h at 37°C. Nonspecific binding 
was determined in separate wells by performing the assay in the 
presence of 400 i~g/ml unlabeled fibronectin (+Fn). After the in- 
cubation, unbound protein was removed, wells were rinsed, and 
bound material was solubilized in sample buffer and counted to 
determine radioactivity. Data are presented  as total cpm bound. 
(B) Samples containing 1.5 x 104 cpm from HDIII-10  and HDIII-1 
wells and  samples of equal  volume  from  corresponding  +Fn 
wells were analyzed on a 10% SDS-PAGE gel under nonreduc- 
ing (NR) and reducing (R) conditions, followed by autoradiogra- 
phy. High molecular mass aggregates are indicated by the arrow. 
The locations of dimeric (D) and monomeric (M) fibronectin are 
indicated to the right of the panels. The migration of a 214-kD 
molecular mass standard  (myosin) is indicated to the left of the 
panels. SM, starting material. (C) Gel slices corresponding to the 
high molecular mass aggregates were removed and counted to de- 
termine radioactivity. Data are presented as total cpm recovered. 
A  Fragment ofllI-lO Inhibits In Vitro 
Multimer Formation 
An amino-terminal fragment of III-10 (III-10A), with an 
apparent molecular mass of 14.5 kD, was generated by di- 
gestion  of  the  GST/III-10 fusion  protein  with  trypsin. 
Amino acid sequencing of III-10 and III-10A  yielded iden- 
tical results, indicating that III-10A is generated by cleav- 
age  of  carboxy-terminal  residues  from  III-10. Whereas 
intact III-10 had no effect on the binding of 1251-111-1 to 
heat-denatured III-10, addition of III-10A to assay wells 
blocked the binding of 1251-111-1 to heat-denatured 111-10 
(not shown), suggesting that the conformation-dependent 
binding site for III-1 is exposed in the III-10A fragment. 
Results from our studies with the 9D2 antibody indicate 
that the interaction of III-1 with the conformation-depen- 
dent site in 111-10 is involved in the formation of fibronec- 
tin  multimers.  To  test  whether  III-10A could  similarly 
inhibit the formation of III-10-induced fibronectin multi- 
mers, 125I-fibronectin  was incubated in wells coated with 
heat-denatured III-10 in the presence of either intact III- 
10 or the III-10A fragment. Addition of III-10A resulted 
in a dose-dependent inhibition of binding of 125I-fibronec- 
tin  to  heat-denatured  III-10 (Fig.  7  C)  and  subsequent 
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Figure 7.  Inhibition of III-10-induced  fibronectin multimers by 
9D2, 27 kD, or III-10A. 24-well plates were  coated with heat- 
denatured III-10, as indicated under Materials and Methods. The 
125I-fibronectin binding assay was performed as indicated in the 
legend to Fig. 6. (A) 0.1, 1, 5, or 10 Ixg/ml 9D2 Fab' fragments or 
10  ~g/ml nonimmune Fab' fragments were  added to the  assay 
wells. (B) 5, 10, 25, or 50 ixg/ml 27 kD or 74 p,g/ml 40 kD were 
added to the assay wells. (C)  1, 5,  or 10 ixg/ml III-10 (hatched 
bars) or III-10A (closed bars) were added to assay wells. Nonspe- 
cific binding was determined in separate wells by performing the 
assay in the presence  of 400 ixg/ml unlabeled fibronectin. Non- 
specific binding was subtracted from total binding to determine 
specific binding. Data are presented as percent specific binding 
determined in the  absence  of inhibitor. Data  represent  one  of 
three experiments done in duplicate. 
multimer formation (not shown). In contrast, intact 111-10 
had no effect on 125I-fibronectin  binding to heat-denatured 
III-10 (Fig. 7 C). These results suggest that the 111-1 bind- 
ing site in III-10 is exposed by proteolytic removal of car- 
boxy-terminal amino acids. 
100-fold  less  than  the  concentration  of  the  ll-kD  cell- 
binding fragment needed to disrupt adhesion of cells to fi- 
bronectin (31). No change in 125I-fibronectin  binding was 
observed with the addition of either 111-2 or intact III-10 
to confluent cell monolayers (not shown). 
Inhibition of  Fibronectin Matrix Assembly by III-IOA 
Addition of the anti-III-1  monoclonal antibody, 9D2,  to 
cell monolayers inhibits the polymerization of fibronectin 
by fibroblasts (5). Our data indicate that the 9D2 antibody 
can inhibit the interaction of III-1  with conformationally 
altered III-10, and that the interaction of III-1 with confor- 
mationally altered III-10 is involved in the formation of in 
vitro  fibronectin  multimers.  It  is  therefore  possible  that 
9D2 blocks fibronectin matrix assembly by binding to the 
III-1  module  of fibronectin molecules  and inhibiting the 
subsequent  interaction  of  III-1  with  III-10  modules  on 
the cell surface. If so, addition of III-10A to cell monolay- 
ers should similarly inhibit fibronectin polymerization by 
cells.  To  test  this  hypothesis,  12sI-fibronectin  binding to 
cell monolayers was determined in the presence of exoge- 
nously added III-10A. As shown in Fig. 8, addition of III- 
10A to confluent A1-F fibroblast monolayers resulted in a 
dose-dependent decrease  in 125I-labeled  fibronectin bind- 
ing to cells in a 24-h fibronectin incorporation assay. No 
apparent change in cell morphology was observed follow- 
ing  incubation  of  cells  with  III-10A  (data  not  shown). 
Complete inhibition of ]25I-fibronectin binding to cell sur- 
faces by III-10A was obtained at a concentration of 20 Ixg/ 
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Figure 8.  125I-fibronectin binding to fibroblasts in the presence of 
III-10A or III-10/RGE. A1-F fibroblasts were seeded at 5  ×  104 
cell/ml in 24-well tissue culture plates  and grown to confluence, 
Media was removed and cells were washed with DMEM. Cells 
were then incubated  with 0.25  ml DMEM/0.2%BSA containing 
0.5  )<  10 6 cpm/ml 125I-fibronectin, in the absence or presence of 5, 
10, or 20 t~g/ml III-10A (©) or III-10/RGE (e) for 24 h at 37°C. 
Cell layers were then washed three times with PBS  and bound 
protein was solubilized with 1 N  NaOH. Data are expressed as 
mean  -+  standard error and  represent one  of two  experiments 
performed in triplicate. 
The Journal of Cell Biology, Volume 133, 1996  438 Figure9. Immunofluorescent colocalizationoflII-1,2and131integrinsonfibroblasts. A1-Fs (4 × 104 in DMEM/0.2%BSA with 201xg/ml 
cycloheximide) were incubated for 18 h on coverslips coated with 10 p~g/ml of either fibronectin (a-c) or 160/180-kD fibronectin frag- 
ment (d-f). Cells were then stained with 10 p~g/ml  Texas red-conjugated-III-1,2 (b and e) for 90 min at 37°C. Cells were fixed, permeabi- 
lized, and stained for 131 integrins using a monoclonal anti-131 antibody followed by an FITC-conjugated goat anti-rat Fab2 (a and d). The 
IRM image is shown in panels c and f. Arrowheads indicate colocalization of III-1,2 and 131 integrin staining at sites of focal contacts. 
Previous studies have demonstrated that the addition of 
Arg-Gly-Asp peptides  to cell monolayers disrupts the in- 
teraction  of fibronectin  with  the  ets131 integrin  (32)  and 
inhibits  fibronectin  matrix  assembly  (6).  To  determine 
whether the effects of the III-10A fragment on matrix as- 
sembly were due to the disruption  of fibronectin-integrin 
interactions, a recombinant III-10 fragment was produced 
in which the Arg-Gly-Asp sequence was mutated to Arg- 
Hocking et al. Fibronectin's II1-10 Module Interacts with II1-1  439 Figure 10.  Localization  of III-1,2 binding sites. A1-Fs (4 ×  l0  s in DMEM/0.2%BSA with 20 p~g/ml  cycloheximide) were incubated for 
18 h on coverslips coated with 10 Ixg/ml  of Ill-9,10. Cells were then incubated with either media alone (panels a and d), 9D2 (panels b 
and e), or 3E3 (panels c and 3'). Cells were stained with 10 Ixg/ml  Texas red-conjugated-Ill-I,2 (a-c) for 90 min at 37°C. Arrowheads in- 
dicate localization of III-1,2 at sites of focal contacts. The IRM image is shown in d, e, and f. 
Gly-Glu (III-10A/RGE). The  III-10A/RGE module  was 
as  effective  as  the  nonmutant  III-10A in  inhibiting  fi- 
bronectin binding to fibroblast monolayers (Fig. 8), indi- 
cating that the inhibition of fibronectin matrix assembly by 
III-10A was not due to the disruption of fibronectin-ct5131 
integrin interactions. 
Colocalization oflii-1,2 with fll lntegrins 
We postulated that upon binding of fibronectin to the as~  1 
integrin, a conformational change may occur in the III-10 
module which serves to expose the III-1 binding site. If so, 
cell  surface  binding  sites  for  exogenously  added  III-1 
should colocalize with 131 integrins. To test this hypothesis, 
A1-F fibroblasts were seeded onto fibronectin- or 160/180 kD 
fragment-coated coverslips in  the  presence of cyclohexi- 
mide  and  allowed  to  adhere  and  spread for  18  h.  Cells 
were then incubated with Texas red-conjugated 111-1,2 for 
90 min. The 111-1,2 construct was chosen for use in cell as- 
says based on its ability to promote the ternary complex 
with 111-10 and the amino terminus of fibronectin (Fig. 5 
A). In addition, a 14-kD chymotryptic fragment, containing 
portions of both the first and second type III modules, has 
previously been shown to bind to cell surfaces and inhibit 
fibronectin assembly (24). Cells were fixed, permeabilized, 
and stained for 131 integrins using a monoclonal anti-131 an- 
tibody  followed by  an  FITC-conjugated  secondary  anti- 
body. 111-1,2 and 131 integrins were colocalized on the same 
cell using epifluorescence microscopy. As shown in Fig. 9, 
Texas red-conjugated 1II-1,2 staining (panels b and e) was 
detected on cells seeded onto either fibronectin (panels a-c) 
or  the  160/180-kD  fibronectin  fragment  (panels  d-f).  In 
contrast, II1-1,2 staining was not detected  on cells which 
had  been seeded onto either  laminin or vitronectin  (not 
shown).  Moreover, Texas red--conjugated 111-1,2 staining 
was localized to regions of 131-integrin  staining  (Fig. 9, a 
and b), which occurred at areas of focal adhesions, as ob- 
served under IRM optics (Fig. 9, c and f). Similar results 
were observed with cells seeded onto the 160/180-kD frag- 
ment of fibronectin (Fig. 9,  d-f), which does not contain 
the amino-terminal region, indicating that the 111-1,2 was 
not binding directly to the amino terminus. 
Localization of Cell Surface 111-1,2 Binding 
Sites to III-10 
To further localize cell surface III-1,2 binding sites, Texas 
red III-1,2 was incubated with A1-F fibroblasts which had 
been  seeded  overnight  onto  coverslips coated with  a  fi- 
bronectin construct containing the  III-9 and  III-10 mod- 
ules  (III-9,10).  This  construct  contains  the  synergy  site 
within the II1-9 module that is required for cell spreading 
(3, 29). Binding sites for Texas red III-1,2 were observed 
on the surface of cells adherent to III-9,10 (Fig.  10 a, ar- 
rowheads).  These sites also localized to focal adhesions, as 
observed  under  IRM  optics  (Fig.  10  d,  arrowheads). 
1~5I-III-1,2, in the absence of cells, did not bind to cover- 
slips coated with III-9,10 (not shown), indicating that the 
interaction of the cell with III-9,10 was required for the ex- 
pression of III-1,2 binding sites. To localize III-1,2 binding 
to the III-10 module, cells adherent to III-9,10 were incu- 
bated with 50  txg/ml  of either  the  anti-III-1 monoclonal 
antibody,  9D2,  or  the  monoclonal  antibody  3E3.  Clone 
3E3  has  previously been  shown  to  recognize  the  15-kD 
cell-binding fragment of fibronectin  (33)  and  recognizes 
the III-9,10 construct in Western blots (data not shown). 
After 1-h incubation, Texas red 111-1,2 was added directly 
to  the  culture  media and  cells were  incubated  an  addi- 
The Journal of Cell Biology,  Volume 133, 1996  440 Figure 11.  Inhibition of 111-1,2 binding site expression by monoclonal antibody 3E3. A1-Fs (4 x 105 in DMEM/0.2%BSA with 20 p~g/ml 
cycloheximide) were incubated for 18 h on coverslips coated with 10 p~g/ml of the 160/180-kD fragments of fibronectin. Cells were then 
incubated with either media alone (a and d), 3E3 (b and e), or LAB (c and f). Cells were stained with 10 ixg/ml Texas red-conjugated- 
III-1,2 (a-c) for 90 min at 37°C. Arrowheads indicate localization of III-1,2 at sites of focal contacts. The IRM image is shown in d, e, and f. 
tional 90 min. Addition of either 9D2 (Fig.  10 b) or 3E3 
(Fig.  10 c) completely inhibited the binding of 111-1,2 to 
cell  surfaces.  Inhibition of 11I-1,2 binding by the  mono- 
clonal antibodies was not due to disruption of cell adhe- 
sion,  since sites  of focal adhesions were  observed in the 
presence of either  9D2 or 3E3  (Fig.  10,  e  and f,  arrow- 
heads). These data suggest that the binding of III-1 to III- 
10 is required for the localization of 111-1,2 to the integrin/ 
111-9,10 complex. 
To determine  if type III modules of fibronectin other 
than III-10 could serve as 111-1,2 binding sites on cell sur- 
faces during the  initiation  of fibronectin polymerization, 
A1-F fibroblasts were plated onto coverslips coated with 
the 160/180-kD fragments of fibronectin and allowed to ad- 
here and spread for 18 h. As previously shown (Fig.  9 b), 
cells adherent to the 160/180-kD fragments of fibronectin 
expressed 111-1,2 binding sites on their surfaces (Fig. 11 a, 
arrowheads).  Addition of either  3E3  (Fig.  11  b)  or 9D2 
(not shown) inhibited the expression of cell surface III-1,2 
binding sites.  In contrast, addition of the monoclonal anti- 
body Lab, which recognizes an epitope within the region 
111-4 to 111-8 (5), had no efffect on 111-1,2 binding site ex- 
pression  (Fig.  11  c).  Similar  results  were  obtained  with 
cells seeded onto intact fibronectin (not shown). Taken to- 
gether, these data suggest that on cells  newly adherent to 
protomeric fibronectin, the III-10 module serves as a cell 
surface binding site for III-1. 
Discussion 
We have recently reported that the amino terminus of fi- 
bronectin binds to a  conformation-dependent site within 
the  III-1  module  of  fibronectin  (15).  In  addition,  the 
amino-terminal region of fibronectin was shown to bind to 
trypsinized cell surface fibronectin fragments which con- 
tained the 111-1 module (15) and to a recombinant fusion 
protein containing the first two type III repeats  (1), sug- 
gesting that the interaction of the amino terminus with III-1 
may be one of the homophilic interactions which occurs 
during the process of fibronectin matrix assembly. In the 
present study, we have defined a second homophilic inter- 
action which may also function during the process of fi- 
bronectin polymerization. Our data indicate that the III-1 
module also binds to a conformation-dependent site in the 
integrin-binding III-10 module. In addition, our data indi- 
cate that in the absence of cells,  the interaction of III-1 in 
intact fibronectin with the conformation-dependent site in 
III-10 leads  to the  formation of high molecular mass fi- 
bronectin multimers through an interaction which involves 
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mechanism  whereby the  interaction of III-10 with  III-1 
promotes a conformational change within the III-1 mod- 
ule which unmasks  the  amino-terminal binding site  and 
triggers the self-polymerization of fibronectin. 
A role for the cell-binding domain of fibronectin in ma- 
trix assembly was previously demonstrated in a study by 
McDonald et al. (20), in which addition of either a 105-kD 
cell-binding fibronectin fragment  or  antibodies  directed 
against this fragment inhibited matrix assembly. In addi- 
tion, studies have demonstrated a role for lII-1 in fibronec- 
tin matrix assembly (5, 24). The anti-III-1 monoclonal an- 
tibody, 9D2, has been shown to block the incorporation of 
exogenous fibronectin into the extracellular matrix (5). In 
addition,  a  14-kD  fibronectin  fragment,  beginning  20  ° 
amino acid residues into the III-1 module, was shown to 
bind to both intact fibronectin and cell layers, and to block 
matrix assembly (24). Neither the 9D2 antibody nor the 
14-kD fragment inhibited the binding of the 70-kD frag- 
ment to cells (5, 24). Similarly, in the present study, 9D2 
had no effect on the ability of the 70-kD fragment to bind 
to II1-1. On the other hand, 9D2 was able to completely in- 
hibit the interaction of III-1 with 111-10, at concentrations 
similar to those previously shown to block fibronectin po- 
lymerization on cell surfaces (5). It is possible, therefore, 
that one mechanism by which both 9D2 and the  14-kD 
fragment inhibit  fibronectin polymerization on cell sur- 
faces is by inhibiting the interaction of III-1 with III-10. In 
support of this is our observation that addition of the III-10 
fragment (III-10A) to fibroblast monolayers also resulted 
in the inhibition of fibronectin polymerization. The ability 
of III-10A to inhibit fibronectin polymerization was not 
due  to a  disruption  of cell adhesion,  since  the  III-10A/ 
RGE  construct, in which  the  integrin-binding  RGD  se- 
quence was mutated to RGE (32), was also able to inhibit 
fibronectin polymerization. These results suggest that the 
III-10 module in fibronectin participates in a step in matrix 
assembly which is distinct from its integrin-binding activity. 
Upon binding of the amino-terminal region to the cell 
surface, fibronectin accumulates in the extracellular ma- 
trix in the form of high molecular mass  aggregates (21). 
Cell-mediated fibronectin polymerization can be blocked 
by the addition of either amino-terminal fragments of fi- 
bronectin (22, 35) or the 9D2 antibody (5). In the present 
study, the interaction of fibronectin with conformationaUy 
altered 111-10, in the absence of cells, resulted in the for- 
mation  of  disulfide-stabilized  high  molecular  mass  fi- 
bronectin multimers, via an interaction involving the amino- 
terminal  region  of fibronectin.  Although  earlier  studies 
have demonstrated in vitro fibronectin multimer forma- 
tion through either the oxidation of free sulfhydryls (27), 
the use of reducing agents (46), or the addition of metal 
ions (43), the ability of both 9D2 and the 27-kD fibronec- 
tin fragment to inhibit III-10-induced fibronectin multi- 
met formation suggests that the mechanisms involved in 
the formation of III-100induced multimers may be similar 
to those which mediate polymerization of fibronectin on 
cell surfaces. Morla et al. (25) have demonstrated that a fi- 
bronectin construct containing a portion of the III-1 mod- 
ule was able to induce fibronectin multimer formation by a 
mechanism which also involved the amino-terminal region 
of fibronectin. The authors suggested that the site in the 
III-1  construct  which  promotes  multimer  formation  is 
cryptic within the III-1 module of intact fibronectin (25).. 
In the present  study, the  ability of conformationally al-" 
tered III-10 to trigger fibronectin multimer formation in- 
volved both the 111-1 module and the amino terminus, sug- 
gesting that the cryptic site in III-1 may be unmasked upon 
its interaction with III-10. In addition, whereas binding of 
fibronectin to heat-denatured  III-1  could be completely 
inhibited by the addition of excess amino-terminal 70-kD 
fragment, this interaction failed to trigger fibronectin mul- 
timer formation, suggesting that both the III-10 and amino- 
terminal binding sites in III-1 must be accessible during 
multimer formation. 
On cell surfaces, fibronectin fibrils (36) and amino-ter- 
minal 70-kD fibronectin fragment binding sites (7)  have 
been shown to colocalize with etsI31 integrins in focal adhe- 
sions. In addition, anti-[3~ integrin antibodies inhibit bind- 
ing of the amino-terminal 70-kD fragment to the cell sur- 
face, suggesting  that  the  ot5131 integrin  can  regulate  the 
expression of amino-terminal binding sites (9). One of the 
functions of integrins in matrix assembly, therefore, may 
be to provide adhesion sites in which fibronectin, bound to 
the integrin, undergoes a series of conformational changes 
resulting in the  exposure of the  amino-terminal binding 
site in III-1. In one of the initial steps of matrix assembly, 
binding of the III-10 module to the ot5131 integrin may di- 
rectly alter the conformation of III-10 to expose the 111-1 
binding site. To explore the role of asf31 integrins in the 
regulation  of  this  conformation-dependent binding  site 
within the III-10 module, we examined the expression of 
III-1  binding sites on cell surfaces. In the present study, 
cell surface  binding  sites  for exogenously added  111-1,2 
colocalized with [31 integrins at sites of focal adhesions on 
cells which had been plated onto fibronectin. In addition, 
111-1,2 binding sites were expressed on cell surfaces follow- 
ing adhesion  to the  111-9,10 modules.  Moreover, mono- 
clonal antibodies directed against either III-1 or the 15-kD 
cell-binding fragment blocked binding of II1-1,2  to cells 
plated onto either the II1-9,10 modules or the 160/180-kD 
fragments of fibronectin. Since the 160O80-kD fragments 
contain all of the fibronectin type III repeats, these data 
suggest that on cells adherent to protomeric fibronectin, 
the III-10 module serves as an initial cell surface binding 
site for III-1. The ability of HDIII-5 to support III-1 bind- 
ing (Fig. 2 B) suggests that following the nucleation of fi- 
bronectin matrix assembly and the deposition of fibronec- 
tin into the extracellular matrix, other fibronectin type III 
modules may serve as additional matrix-derived binding 
sites for III-1, particularly during the lateral growth of a fi- 
ber. In the present study, which defines the initial steps in- 
volved in the initiation of fibronectin polymerization from 
protomeric fibronectin, the 3E3 monoclonal antibody was 
found to inhibit completely the cell surface expression of 
II1-1,2 sites on cells plated onto the 111-9,10 construct, the 
160/180-kD fragments of fibronectin, and  protomeric fi- 
bronectin. Taken together, these data are consistent with 
the hypothesis that binding of fibronectin to the etsI31 inte- 
grin regulates the unfolding of the III-10 module to expose 
the 111-1 binding site  during the  initial nucleation of fi- 
bronectin matrix assembly from cell surfaces. 
Although several studies (2, 9,  11, 48) have implicated 
ets~  1 integrins in the formation of fibronectin matrices, fi- 
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ability to form focal contacts and assemble a fibronectin 
matrix,  suggesting  that  other  fibronectin receptors may 
substitute  for the  ctsl31 integrin  during  fibronectin poly- 
merization (52). The ability of other a  subunits to substi- 
tute for a s in fibronectin matrix assembly has been exam- 
ined  using  as-deficient  CHO  ceils.  Expression  of a4~1, 
which  binds  to the  CS1  site located in  the  alternatively 
spliced IIICS region of fibronectin (10,  12, 45), restored 
adhesion and spreading of as-deficient CHO cells on fi- 
bronectin, but did not restore the ability of these cells to 
assemble a fibronectin matrix, suggesting that direct bind- 
ing of the integrin to the III-10 module may be necessary 
for the initiation of matrix assembly (49). Expression of 
av131, which binds to the RGD site in the III-10 module of 
fibronectin (44), restored the ability of as-deficient CHO 
cells to adhere to fibronectin, but did not restore their abil- 
ity to assemble  a  fibronectin matrix (53). In contrast to 
as131-expressing  cells, avl3]-expressing cells demonstrated a 
lower affinity for fibronectin and did not localize avl3] to 
focal adhesions (53). More recently, the activated form of 
a,ib[33 has been shown to promote fibronectin matrix as- 
sembly (50). These data suggest that several components 
may be important in the initiation of matrix assembly, in- 
cluding the direct interaction of the integrin with the 111-10 
module,  the  affinity of the  integrin-fibronectin interac- 
tion, and the ability of the integrin-fibronectin complex to 
localize to focal adhesions. 
In  the  present  study,  we  have  demonstrated  that  the 
III-10  module  of  fibronectin  contains  a  conformation- 
dependent binding site for the III-1 module and that the 
interaction of the III-1 module in intact fibronectin with 
the  unfolded III-10 module promotes the  generation of 
high molecular mass multimers through an interaction in- 
volving the amino-terminal region of fibronectin. Our data 
are consistent with a model in which de novo nucleation of 
fibronectin matrix assembly is initiated by sequential in- 
teractions involving the integrin and the 111-10 and III-1 
modules  of fibronectin.  The  interaction  between  III-10 
and III-1 is blocked by the 9D2 monoclonal antibody. The 
inability of the 9D2 monoclonal antibody to inhibit either 
70-kD binding to cell monolayers (5) or to heat-denatured 
III-1  (Fig.  4  B)  suggests  that  the  initial  binding  of the 
amino terminus of fibronectin to the cell surface is medi- 
Figure  12.  Model  of  III-1/III-10/integrin  nucleation  site.  Sche- 
matic representation  of fibronectin  nucleation site in which the 
binding of the ct5131 integrin to the III-10 module in protomeric fi- 
bronectin exposes the III-1 binding site in III-10. Upon binding of 
a  II1-1  module  to  the  unfolded  II1-10,  the  70-kD  binding  site 
within the III-1 module is exposed, allowing the amino terminus 
of an incoming fibronectin molecule to be transferred to the III-1 
module of the growing fibril.  Addition of either 9D2 or III-10A 
inhibits  the  interaction  of  III-1  with  III-10  and  prevents  the 
movement of 70 kD onto the nucleation complex. 
ated by another molecule. Our model, depicted in Fig. 12, 
predicts that once the III-10/III-1 complex is formed, the 
amino terminus is transferred from the binding site on the 
cell to the III-1 module. This model addresses the de novo 
nucleation of matrix asembly from cells adherent to proto- 
meric fibronectin, and  does not  preclude the possibility 
that fibronectin polymerization may be initiated or propa- 
gated from other sites when cells are adherent to other 
matrix molecules. 
The presence of an established fibronectin matrix may 
support  the  incorporation  of  dimeric  fibronectin  con- 
structs lacking either the RGD sequence or the III-1 mod- 
ule (18, 40). These studies did not distinguish between the 
ability of the fibronectin construct to bind to a preexisting 
fibronectin matrix and to actually undergo polymerization 
into fibrils. The studies presented here would suggest that 
such constructs would not undergo polymerization in the 
absence of a preexisting fibronectin matrix. In agreement 
with this, a dimeric construct containing only the amino- 
terminal 70-kD region and the carboxy-terminal bridge re- 
gion of fibronectin has been shown to be incorporated into 
the extracellular matrix (42). However, the dimeric 70-kD 
construct  accumulated  in  the  matrix  of cycloheximide- 
treated cells only in the presence of intact fibronectin (42). 
These data suggest that once the nucleation site is estab- 
lished, by either endogenous fibronectin or exogenously 
added fibronectin, subsequent  interactions involving the 
unfolded  III-1  module  in  the  nucleation  site,  and  the 
amino terminus of an incoming fibronectin molecule leads 
to the incorporation of the fibronectin molecule into the 
extracellular matrix. We propose that following initial ad- 
hesion of cells to protomeric fibronectin, nucleation of fi- 
bronectin matrix assembly occurs by an  integrin-depen- 
dent unfolding of the III-10 domain which regulates the 
subsequent interaction between the unfolded III-10 mod- 
ule and the III-1 module of another fibronectin molecule. 
By controlling the interaction of III-10 with III-1, the 131 
integrin thereby regulates the conformation of III-1, and, 
consequently, the polymerization of incoming fibronectin 
molecules into fibrils. Taken together, these data suggest 
that the nucleation of fibronectin polymerization proceeds 
by a series of sequential self-interactions which are regu- 
lated  by the  integrin-dependent  unfolding of the  III-10 
module. 
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